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Abstract
Excessive production of TNF-a cytokine by cardiomyocytes in response to
lipopolysaccharides (LPS) contributes to myocardial depression during sepsis. However,
the exact mechanism by which TNF-a is produced in cardiomyocytes is partly
understood. This study investigated the role o f Sirtuinl (SIRT1) in LPS-induced TNF-a
expression in cardiomyocytes.

LPS increased SIRT1 activity in cultured mice cardiomyocytes. Knockdown of
SIRT1 gene reduced TNF-a synthesis in LPS treated cells. Inhibition o f SIRT1 reduced
TNF-a mRNA and protein, whereas activation of SIRT1 enhanced TNF-a mRNA and
protein in LPS stimulated cells. SIRT1 signalling was also associated with activation of
NF- kB transcription factor. Further, in vivo study demonstrated that TNF-a mRNA and
protein levels were significantly lower in SIRT1 knockout mice compared to wild-type
mice during endotoxemia. Results suggest that SIRT1 induces TNF-a expression in LPS
stimulated cardiomyocytes through NF- kB activation. Therefore, targeting SIRT1
signalling may be therapeutically significant in minimizing myocardial depression in
septic hearts.
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Chapter 1: Introduction
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1.1

Sepsis

Sepsis is a serious life-threatening medical condition that is characterized by
systemic inflammation. It can be defined as an overwhelming inflammatory response to
an invading pathogen. It is the leading cause o f death in intensive care units [1], Sepsis is
a major and increasing cause of mortality and morbidity throughout the world with an
annual incidence o f 3 cases per 1,000 in the population [2]. Mortality rate rises from 2 5 30% for severe sepsis to 40-70% for septic shock [3]. According to data from the
Centers for Disease Control and Prevention, it is the 10 most common cause of death
overall [4],

Sepsis is considered a three-stage syndrome, starting with sepsis and progressing
through severe sepsis to septic shock. Normally, the body's defence system fights
infection, but during sepsis inflammatory response it becomes generalized due to
infection spreading via the bloodstream and extending to tissues distant from the original
site o f infection. This results in body's normal reaction going into an overdrive. Humoral
immune response causes cytokines, important immune chemicals to be released by
immune cells into the blood to combat the infection. Septicemia triggers a cascade of
events that can lead to widespread inflammation, which leads to blood clots and leaky
vessels. This results in severe sepsis where there is impaired blood flow, which damages
the body’s organs by depriving them o f nutrients and oxygen causing acute organ
dysfunction. If the situation persists, one or more organs fail and this condition is known
as septic shock [5].

3

1.2

Events in sepsis

An initial toxic stimulus triggers the production of proinflammatory cytokines
and increases monocyte adherence to endothelial cells. These cytokines, in turn, result in
activation o f neutrophils and neutrophil-endothelial cell adhesion. Activation of
neutrophils leads to generation of numerous secondary inflammatory mediators,
including cytokines, clotting factors, prostaglandins, leukotrienes, bradykinins, NO
(nitric oxide) and proteases further amplifying the inflammatory response. Anti
inflammatory compounds, such as IL-6 (interleukin-6) and 1L-10 (interleukin-10), that
may serve as negative feedback to the inflammatory process are also released. Activation
of platelets and increased production o f procoagulants by endothelial cells may trigger
microthrombosis. In some cases, DIC (disseminated intravascular coagulation) may
occur with life-threatening tissue ischemia [6].

Vessel dilation is caused by free radicals, histamine, prostaglandins, prostacyclin,
and the kinin and tachykinin family of molecules. This combined with the effects of
cytokines on the endothelial cells contributes to increased vascular permeability for
fluids and low-molecular weight substances, causing edema. If the process is wide
spread, capillary leak syndrome may result. In some cases erythrocytes may leak out and
cause bleeding [7] (Figure 1.1).

1.3

Lipopolysaccharides (LPS)

LPS is an essential component of the cell wall o f the Gram negative bacteria. It is
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B endtzen 1998
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Figure 1.1 Immunologic response in sepsis

LPS stimulates monocytes to produce proinflammatory cytokines and increases
their adherence to endothelial cells. Proinflammatory cytokines further activate
neutrophils and result in increased neutrophil-endothelial-cell adhesion. Secondary
inflammatory mediators are released by neutrophils and this increases vascular
permeability resulting in edema and hemorrhage.
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a major part o f a lipoprotein structure with a core of polysaccharide that links the
lipoprotein, anchored in the membrane, to the outer chains of saccharides by a covalent
bond. It consists o f a lipoidal acylated glucosamine disaccharide and a linking core of
phosphorylated heptose and keto-deoxyoctonate. It is highly conserved throughout most
species of Gram negative bacteria [8].

LPS or endotoxin is unique to Gram negative bacteria. The LPS structure is
present deep within the intact cell membrane o f the bacteria. Interaction of this structure
with host tissue occurs predominantly during growth phases of the bacteria, during cell
lysis by host clearance mechanisms such as complement fixation, or during cell lysis
after antibiotic action.

LPS induces proinflammatory responses via its receptors TLR-4 (toll-like
receptor 4) and CD 14 (cluster of differentiation 14) after binding to lipopolysaccharidebinding protein (LBP) [9, 10]. The MD-2 (lymphocyte antigen 96) protein appears to
associate with TLR4 on the cell surface and confers responsiveness to LPS, thus
providing a link between the receptor and LPS signalling [11] (Figure 1.2).

NOD (Nucleotide-binding oligomerization domain) proteins have also been
shown to respond to LPS intracellularly. The mechanism by which NOD proteins
recognize LPS in the cytosol however is unknown [12]. There are other cell surface
molecules that sense LPS in immune cells, such as MSR (macrophage scavenger
receptor), CD1 lb/CD18 and ion channels [13, 14].

Once LPS-LBP complex binds to TLR4, the intracellular signalling depends on
binding of the intracellular TLR domain, TIR (Toll/IL-1 receptor homology domain), to

6

Cytokines and effector molecules

\

Figure 1.2 M olecular mechanism of LPS mediated TNF-a expression

Diagrammatic representation of cell-surface recognition of LPS and the
downstream mechanisms leading to NF- kB activation and TNF-a transcription. (Source:
Cohen J, The immunopathogenesis o f sepsis. Nature, 2002. 420(6917): p. 885-91)
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IRAK (IL-1 receptor-associated kinase) [15]. This process is facilitated by two adapter
proteins, MyD88 (myeloid differentiation protein 88) and TIRAP/Mal (TIR domaincontaining adapter protein/MyD88-adapter-like protein), and inhibited by Tollip (toll
interacting protein) [16]. The MyD88 further signals through TRAF6 (TNF receptor
associated factor 6), which interacts with IKK (I kappa B kinase) complex or MAPK
(mitogen-activated protein kinases) [17], MAPK has been demonstrated to be an
essential signalling mechanism governing the regulation of pro-inflammatory responses
[18]. The MyD88-independent pathway is less understood and it has been shown that
TIRAP/Mal can signal through PKR (RNA-dependent protein kinase) or IRF3
(interferon regulatory factor-3) [18]. IRF3 signalling has been shown to enhance
cytokine expression, whereas PKR activates the IKK complex [19].

N F - k B (nuclear factor-kappa B) is present in almost all animal cell types and

performs a vital role in mediating cellular responses to stress, inflammation, the immune
response and apoptosis. It is a transcription factor that consists of p50, p65 and IkB (I
kappa B) subunits present as a heterodimeric complex in the cytoplasm [20]. I kB acts as
an inhibitor protein by inactivating the p50/p65 heterodimer by masking the N F - kB
nuclear localization sequences, thus preventing it from entering the nucleus. Extracellular
signals, such as pathogens or cytokines activate IKK which phosphorylate and
subsequently lysis the IkB, allowing active p50/p65 heterodimer to translocate into the
nucleus and cause cytokine expression [20] (Figure 1.3).

A variety o f recent evidence, however, indicates that the control of the NF-kB
pathway is more complex than simply IKK-mediated IkB regulation. Studies have
associated ROS (reactive oxygen species) release to NF-kB activation during LPS
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Figure 1.3 N F- k B activation
Phosphorylation and subsequent proteolytic degradation of the inhibitory protein
Ik B by IKK activates N F - kB. Free heterodimer p50/p65 then passes into the nucleus and

causes expression o f cytokines. (Source: Barnes PJ, Karin M, Nuclear factor-kb — A
pivotal transcription factor in chronic inflammatory diseases. The New England Journal
of Medicine, 1997. 336(15): p. 1066-71)
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stimulation by TLR4 dependent and independent pathways [21]. Ubiquitination of IkB
has been shown to releases p50/p65 heterodimer, allowing it to bind to its cognate DNAbinding site in the nucleus [22]. Various deacetylase enzymes have recently emerged as
being important in the control and activation o f the p65 subunit [23]. Méthylation o f p65
has also been reported to inhibit the transcriptional activity of N F- kB [24], Additionally,
prolyl isomerisation of p65 results in increased nuclear accumulation and protein
stability o f p65 and enhanced N F - kB activity [25]. In cardiomyocytes JAK/STAT (Janus
kinase/signal transducer and activator o f transcription) signalling pathway is known to
initiate N F - kB transcription and cytokines are reported to bind to receptors that activate
this pathway [26].

1.4

Tumor necrosis factor - alpha (TNF-a)

TNF-a is a cytokine involved in systemic inflammation and is manufactured by
white blood cells to stimulate and activate the immune system in response to infection. It
has a number o f actions on various organ systems, generally together with IL-1
(Interleukin-1) and IL-6 (Interleukin-6). The primary role of TNF-a is the regulation
of immune cells. Other biological activities o f TNF-a includes, inducing apoptotic cell
death, triggering inflammation, modulating the properties of the vascular endothelium
and inhibiting tumorigenesis and viral replication.

Large amounts of TNF-a is released in response to LPS and other bacterial
products. When TNF-a release in response to LPS during sepsis increases to such an
extent that it escapes the local infection and enters blood stream, sepsis ensues.
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Excessive production o f TNF-a can lead to autoimmune diseases, where the immune
system acts against healthy tissues and plays a significant role in organ dysfunction and
failure. Dysregulation o f TNF-a production has been implicated in a variety of clinical
problems associated with disorders, including rheumatoid arthritis [27], ankylosing
spondylitis [28], Crohn's disease [29], psoriasis [30], asthma [31], Alzheimer's disease
[32] and cancer [33]. These diseases are often times treated with expensive biological
drugs known as TNF inhibitors. These drugs bind and inactivate TNF-a, thereby
reducing unhealthy inflammation. This inhibition can be achieved with monoclonal
antibodies

such as

infliximab

(Remicade),

adalimumab

(Humira), certolizumab

pegol (Cimzia), golimumab (Simponi), or with a circulating receptor fusion protein such
as etanercept (Enbrel) [34], Xanthine derivatives, such as pentoxifylline and bupropion
have also been shown to be effective inhibitors [35]. The global market for TNF
inhibitors in 2008 alone was $13.5Bn [36].

TNF-a is produced mainly by macrophages, monocytes and neutrophils, but it is
also produced by a broad variety of cell types including lymphoid cells, adipose
tissue, mast cells, fibroblasts, neuronal tissue and cardiomyocytes. LPS-induced TNF-a
significantly contributes to myocardial dysfunction during sepsis [37], Cardiomyocytes
are known to act as a main local source o f TNF-a production in the heart [37]. Both in
vivo and in vitro studies have suggested that TNF-a production in the myocardium
impairs cardiac contractile function and contributes to myocardial dysfunction during
sepsis [38, 39].
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1.5

Septic myocardial dysfunction

Cardiomyocytes are cardiac muscle cells and the basic functional unit of the
myocardium. They are involuntary striated muscle cells. Similar to skeletal muscle cells,
they contain sarcomeres. While skeletal muscles are arranged in regular and parallel
bundles, cardiac muscles connect at branching and irregular angles called intercalated
discs. The heart produces and utilizes more energy than any other organ, and more than
90% o f its energy is produced from mitochondrial respiration [40], Normal cardiac
function can be maintained only if ATP is continuously re-synthesized [41]. To meet this
high energy demand, cardiomyocytes have the highest density of mitochondria among all
mammalian organs and occupy 30% o f the heart volume [40]. This enables continuous
aerobic respiration via oxidative phosphorylation and hence adapting them to be highly
resistant to fatigue. Abundant myoglobins, which are oxygen-storing pigments and a
good blood supply providing nutrients and oxygen plays a vital role in continuous
cardiac muscle cell contractions.

Septic myocardial dysfunction includes cardiac abnormalities such as various
degrees of ventricular systolic and diastolic dysfunction [42], When the cardiovascular
system begins to fail, blood pressure drops depriving vital organs o f an adequate
oxygenated blood supply. Forty-50% o f patients with prolonged septic shock develop
myocardial dysfunction [43], The occurrence o f cardiovascular dysfunction in sepsis is
associated with a significantly increased mortality rate of 70-90% compared with 2030% in septic patients without cardiovascular impairment [44], Excessive TNF-a
synthesized by cardiomyocytes in response to LPS plays a significant role in septic
myocardial dysfunction [37].
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Cardiomyocytes have been shown to secrete several cytokines apart from TNF-a,
such as IL -ip (Interleukin-1(3), IL-6 (Interleukin-6) and MIF (macrophage migration
inhibitory factor) in response to LPS and directly depress myocardial contractility [39,
45]. They also generate chemoattractants o f immune cells, such as CINC-1 (cytokineinduced neutrophil chemoattractant-1) and HMGB-1 (high-mobility group box-1) [46,
47], Sepsis leads to intensive activation of complement anaphylatoxins and C5a
(complement component 5a) is considered one of the most potent inflammatory peptides.
Enhanced expression o f C5aR (C5a receptor) on cardiomyocytes causes C5a-C5aR
interaction resulting in the compromise o f cardiac performance [48]. Cardiomyocytes
also express TLRs (toll-like receptors) that recognize structurally conserved molecules
derived from microbes, such as LPS and play a critical role in evoking the innate
immune system [10]. Abnormalities in the myocardial calcium current and increased
intracellular Ca2+ overload have been described in cardiomyocytes when excessive TNFa or IL-1J3 is present [49]. Elevated TNF-a and IL-6 level in heart has been shown to
inversely correlated to left ventricular function [50], LPS induces the formation of iNOS
(inducible nitric oxide synthase) and eNOS (endothelial nitric oxide synthase) in
cardiomyocytes [51, 52], These nitric oxide synthase isoforms catalyse the formation of
NO (nitric oxide), which is known to enhance cytokine expression [53], These are
paradoxical phenomenons, as the molecules expressed by the cardiomyocytes to combat
infection, also impair cardiomyocyte performance.

Cardiovascular changes in sepsis include decreased vascular tonus and
myocardial contractility [54]. The circulating levels of TNF-a have been correlated with
the severity of chronic heart failure and coexisting cachexia [55], TNF-a is one of the
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most important mediator of inflammatory response during the pathological progression
of myocardial ischemia, reperfusion and hypertrophy [56, 57]. It is also involved in
pathogenesis o f myocardial infarction, atherosclerosis, myocarditis and cardiac allograft
rejection [58-61]. Modulation of TNF-a level in cardiomyocytes will therefore be of
therapeutic significance in reducing myocardial dysfunction induced by endotoxemia.
However, the exact mechanism by which LPS induces TNF-a in the myocardium during
sepsis remains not fully understood.

1.6

Sirtuins

Sirtuins (silent information regulators) are an evolutionarily conserved category
o f proteins that function as intracellular regulatory enzymes due to either histone
deacetylase or mono-ribosyltransferase activity and are found in organisms ranging from
bacteria to humans [62]. In mammals, seven sirtuin isoforms (SIRT1-7) have been
identified [63]. They are ubiquitous enzymes that occupy different subcellular
compartments such as the nucleus (SIRT1, 2, 6 and 7), cytoplasm (SIRT1 and SIRT2)
and the mitochondria (SIRT3, 4 and 5) [64], They are suspected to influence a variety o f
physiological processes. SIRT1 deficiency has been shown to result in perinatal deaths
and retinal, bone and cardiac defects [65], SIRT2, localized in the nucleus and in the
cytoplasm has been found to be important for chromosomal stability during mitosis [66].
SIRT3, SIRT4, and SIRT5 are localized predominantly in mitochondria and are referred
to as mitochondrial stress sensors that can modulate the activity of several mitochondrial
proteins involved in metabolism [67]. SIRT6 is a chromatin-associated sirtuin analogue

14

involved in the regulation of diverse cellular functions like genomic stability, glucose
homeostasis

and

inflammation

[68-70].

SIRT6

deficient mice

show

complex

degenerative phenotype, enhanced rate o f ageing and hypoglycaemia [65, 71]. The last
member o f this family, SIRT7 is found to be associated with nucleoli and condensed
chromosomes [72, 73]. SIRT7 deficient mice have reduced lifespan and develop cardiac
hypertrophy and inflammatory cardiomyopathy [65, 74]. Sirtuins have considerable
redundancy in targets and regulate the fundamental aspects of longevity like cell
survival, metabolism and stress resistance [64]. Beneficial cardiovascular effect of
sirtuins by preventing hypertrophy, protecting myocytes against oxidative stress and
improving cardiac function in diabetic cardiomyopathy has also been reported [75, 76].
They are increasingly thought to underlie many o f the health benefits o f calorie
restriction [77].

What makes sirtuins distinct from other deacetylases is their requirement for
NAD+ (nicotinamide adenine dinucleotide) as a co-substrate [62]. NAD+ is a coenzyme
found

in

all

cells.

In

metabolism,

NAD+ is

involved

in

redox reactions,

carrying electrons from one reaction to another. Reliance of sirtuins upon NAD+ plays a
great role in connecting their enzymatic activity directly to the grade of energy of the cell
by means o f the cellular NAD+:NADH ratio, the absolute levels of NAD+, NADH or
nicotinamide (vitamin B3) or a combination o f these variables [78], Different from other
recognized protein deacetylases, which hydrolyze acetyl-lysine residues, the sirtuinmediated deacetylation reaction couples lysine deacetylation to NAD+ hydrolysis [79],
This hydrolysis

generates

O-acetyl-ADP-ribose,

the deacetylated

substrate and

nicotinamide [79] (Figure 1.4). Nicotinamide is an obstructer of sirtuin activity and thus
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2-0 acetyl ADP ribose

NAD

Nicotinamide

SIRT1

NH-CO-CHj

Acetylated protein

Deacetylated protein

V
Figure 1.4 SIRT1 deacetylation reaction

S1RT1 catalyzes the deacetylation of proteins by removing acetyl groups from
lysine in the presence of NAD+. The acetyl group from the lysine gets added to the ADPribose part of NAD+ to form O-acetyl-ADP-ribose and nicotinamide. (Source: Pillarisetti
S, A review o f Sirtl and Sirtl modulators in cardiovascular and metabolic diseases.
Recent Pat Cardiovasc Drug Discov, 2008. 3(3): p. 156-64)
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acts in a negative feedback loop to inhibit the activation of sirtuins. Free nicotinamide
binds to a conserved pocket that participates in NAD+binding and catalysis and
promotes a base-exchange reaction at the expense of deacetylation, hence inhibiting the
activation o f sirtuins [80].

1.7

Sirtuin 1

SIRT1 is a member of the sirtuin family of proteins. It is the closest mammalian
homologue o f yeast sirtuin 2 [81]. SIRT1 is present both in the nucleus and in the
cytoplasm and is known as a class III histone deacetylase [81]. It can deacetylate a
variety o f substrates and is therefore involved in a broad range of physiological
functions, including gene expression, cell survival, aging, metabolism and stress
response [77, 82, 83]. It deacetylates both acetylated histone and many non-histone
proteins including p53 (protein 53), FoxO (forkhead box O), eNOS (endothelial nitric
oxide

synthases),

P G C la

(peroxisome

proliferator-activated

receptor

gamma

coactivator-1 alpha), LKB1 (liver kinase B l), LXR (liver X receptor), HIF-2a (hypoxiainducible factor 2a), TORC2 (transducer o f regulated CREB activity 2), IRS-2 (insulin
receptor substrate 2), PPARy (peroxisome proliferator-activated receptor gamma) and
NF-kB [83-90],

SIRT1 is implicated in various cellular functions (Figure 1.5). It has been shown
to assist in the repair of DNA and regulates genes that undergo altered expression with
age [91]. SIRT1 is also involved in epigenetic gene silencing after recruitment to the
nucleus [92], SIRT1 influences a wide and growing variety of processes including
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Figure 1.5 Diverse physiological roles of SIRT1
Schematic representation of SIRT1 regulated intracellular parameters and organspecific physiology. (Source: Finkel T, Deng CX and Mostoslavsky R, Recent progress
in the biology and physiology o fsir tuins. Nature, 2009. 460(7255): p. 587-91)
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autophagy, apoptosis, senescence and muscle differentiation [65]. This enzyme may also
regulate the circadian clock of the cell in response to metabolic conditions [65]. SIRT1
also controls neuronal differentiation and increases resistance to neurodegeneration [93].
SIRT1 is downregulated in cells that have high insulin resistance and inducing its
expression increases insulin sensitivity [94]. Research has also implicated that SIRT1
acts as a regulator of energy and metabolic homoeostasis in humans [95],

Previous research has shown the involvement of SIRT1 in various physiological
roles in the heart. Low to moderate overexpression of SIRT1 in the heart was found to be
cardioprotective, whereas its high-level expression was associated with the development
o f cardiomyopathy [96], SIRT1 can also protect against oxidative stress by lowering
levels o f ROS through changes in mitochondrial function [97]. Autophagy and
antioxidants activated by the SIRTl-FoxOl pathway is beneficial for the heart during
nutrient deficiency and ischemia/reperfusion injury respectively [98]. In mice, SIRT1 is
highly expressed in the embryonic heart, and its knockout results in cardiac
developmental defects [99]. Additionally, SIRT1 has been reported to improve cardiac
function in diabetic cardiomyopathy [75], Resveratrol is known to activate the SIRT1
gene through an allosteric interaction, resulting in the increase of SIRT1 affinity for
NAD+ [100]. Adding resveratrol to the diet of mice inhibits gene expression profiles
associated with muscle aging and age-related cardiac dysfunction [ 1 0 1 ].

It has previously been shown that NAD+ biosynthesis pathway mediated by
nicotinamide phosphoribosyltransferase (NAMPT) regulates TNF-a in a SIRT 6
dependent manner in immune cells [102], NAMPT, also known as PBEF (pre-B cell
colony-enhancing factor) and visfatin, is a crucial enzyme in the mammalian NAD+
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salvage pathway. It catalyzes the first step in the biosynthesis of NAD+ by synthesizing
nicotinamide mononucleotide (NMN) from nicotinamide [103]. Both NAMPT and
NAD+ are upstream of SIRT1 and are important in stimulating SIRT1 activity. SIRT1
has previous been shown to regulate p65 subunit of the NF-kB heterodimer through its
deacetylase activity [104]. The role of SIRT1 in inducing TNF-a expression in LPSinduced cardiomyocytes remains unexplored.

1.8

Hypothesis

Herein we review the actions of the SIRT1 enzyme on the cardiomyocytes under
conditions o f sepsis. We hypothesize that SIRT1 promotes TNF-a expression in LPS
stimulated cardiomyocytes through NF-kB activation.

1.9

Specific aims

A. The role o f SIRT1 in LPS-induced TNF-a synthesis in cardiomyocytes.
B. To determine LPS increased SIRT1 activity in cardiomyocytes.
C. To determine whether SIRT1 promotes TNF-a expression in LPS stimulated
cardiomyocytes through NF-kB activation.

1.10

Rationale and significance

Cardiovascular dysfunction in severe sepsis and septic shock remains to be fully
elucidated and there is no cure available to correct this life-threatening condition.
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Expression of TNF-a in response to LPS by cardiomyocytes leads to myocardial
dysfunction, a key manifestation contributing to morbidity and mortality among septic
patients. However, the mechanisms by which LPS induces TNF-a production in
cardiomyocytes remains partly understood. In this study, we are trying to investigate the
role o f SIRT1 in TNF-a expression by LPS.

With this study we expect to demonstrate a novel signalling mechanism which
influences LPS mediated TNF-a expression in cardiomyocytes. This study could provide
potential therapeutic targets to reduce TNF-a production in septic hearts and help
minimize myocardial depression.

Chapter 2: Materials and Methods
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2.1

2.1.1

In vitro Studies

Animals

C57BL/6 wild-type mice were purchased from The Jackson Laboratory. A
breeding program was carried out to produce neonates. All animals were used in
accordance with the guidelines of the Canadian Council on Animal Care, and study
protocols were approved by Animal Use Subcommittee at The University o f Western
Ontario, London, Canada.

2.1.2

Isolation and culture of neonatal mice cardiomyocytes

The hearts from neonatal mice bom within 24hrs were minced and washed in
sodium bicarbonate, Ca2+ and Mg2+ free IX D-Hank’s balance solution (Sigma Aldrich,
St.Louis, MO, USA). The cardiac myocytes were dispersed by addition of liberase
blendzyme (22.5pg/ml, Roche diagnostics, Mannheim, Germany). The cells were
incubated for 15mins at 37°C and then centrifuged at 200g for 5mins to obtain a cell
pellet. The cell pellet were then suspended in DMEM (Dulbecco’s modified Eagle’s
medium, HyClone Laboratories, Thermo Fisher Scientific, Utah, USA) supplemented
with 1% penicillin/streptomycin (Invitrogen, Burlington, ON, Canada) and 10% FBS
(Fetal bovine semm, Gibco, Invitrogen, Grand Island, NY, USA) and were pre-plated on
35mm plates for 90mins to remove non-cardiomyocytes. The cardiomyocytes were then
seeded into Falcon 24well plates pre-coated with 1% gelatin. The cells were incubated at
37°C in a humidified atmosphere containing 5% CO 2. Twenty-four hours later, the
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spontaneously beating cardiomyocytes were subjected to various treatments.

2.1.3

siRNA Transfection

To knockdown the SIRT1 gene in cardiomyocytes, transfection of small
interfering RNAs (siRNA) was performed in cardiomyocytes with TransMessenger™
transfection reagent (Qiagen, Mississauga, ON, Canada), according to the manufacturer’s
instructions. Scrambled siRNA was employed as the control. The siRNAs were
purchased from Santa Cruz Biotech, CA, USA. A mixture of 2.5pl siRNA (lOpM
concentration), 1.5pl Enhancer R and 96pl buffer ECR was vortexed in a tube and
incubated at room temperature for 5mins. To this 4pi TransMessenger™ transfection
reagent was added and the tube was incubated at room temperature for lOmins. One
hundred pi from this tube was used for each well of cells containing lOOpl DMEM
culture media in a 24-well plate. The plate was incubated at 37°C for 4hrs. The wells
were then aspirated and 500pl DMEM supplemented with 1% penicillin/streptomycin
and 10% FBS was added to each well and the cells were incubated overnight before LPS
treatment. The knock-down of SIRT1 siRNA was confirmed by western blot analysis.

2.1.4

Treatment of cardiomyocytes

Cardiomyocytes were treated with the following reagents diluted in DMEM
supplemented with 1% penicillin/streptomycin and 10% FBS, either alone or
combination -

in
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■ LPS (lipopolysaccharides) from Salmonella typhosa, Sigma Aldrich, St.Louis,
MO, USA - 5pg/ml
■ Nicotinamide, Sigma Aldrich, St.Louis, MO, USA - 50pM
■ Resveratrol, Calbiochem, San Diego, CA, USA - lOpM
■ NAD+ (nicotinamide adenine dinucleotide), Calbiochem, EMD Chemicals, Inc.,
USA - 5pM
■ FK866

(N-[4-( 1-benzoyl-4-piperidinyl)butyl]-3-(3-pyridinyl)-2E-propenamide),

Cayman chemical, Ann Arbor, MI, USA - InM
■ Doxorubicin, Novopharm ltd., Toronto, Canada - lpM
■ TSA (trichostatin A), Sigma Aldrich, St.Louis, MO, USA - lpM

2.1.5

RNA Extraction

Total RNA was extracted from cardiomyocytes using the TRIzol Reagent
(Invitrogen, Carlsbad, CA, USA). After cell lysis in TRIzol Reagent, chloroform (EMD
Chemicals, Inc., Gibbs town, NJ, USA) was added. The mixture was vortexed and then
centrifuged at 12000g at 4°C for 15mins. The transparent top layer was transferred to a
new 1.5ml tube, followed by the addition of equal amount of isopropyl alcohol (EMD
Chemicals, Inc., Gibbs town, NJ, USA) to condense the RNA. The mixture was shaken
and then incubated for lOmins at room temperature and then centrifuged at 1 2 0 0 0 g at
4°C for lOmins. After centrifugation, the supernatant was discarded and 1ml 75%
reagent alcohol (VWR International, West Chester, PA, USA) was added to wash the
RNA pellet, followed by centrifugation at 7600g at 4°C for 6 mins. The supernatant was
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discarded and the pellet was left to air dry for 10-15mins. This was followed by addition
of 25 pi of RNase free DEPC water and the tubes were incubated at 65°C for lOmins. The
tubes were then vortexed and kept on ice.

2.1.6

cDNA Synthesis

Reverse transcription was used to transcribe the single stranded mRNA into
complementary cDNA. Using the photometer, the RNA concentration was standardized
in all the tubes. The RNA was then incubated with oligo dT (Sigma Genosys, Oakville,
ON, Canada) primer at 65 °C for lOmin, in which the RNA secondary structure was
denatured. The samples were chilled immediately on ice for 5mins in order for the
primers to anneal to the mRNA. The dNTP (Sigma Aldrich, MO, USA), reverse
transcriptase (Sigma Aldrich, MO, USA) and reverse transcription buffer (Sigma
Aldrich, MO, USA) were then added to the sample to make the volume to 20pi and the
tubes were incubated at 37°C for 50mins. The reaction was inactivated by incubation at
65°C for 5mins to denature the reverse transcriptase. One hundred eighty pi o f RNase
free DEPC water was added to the samples to make the volume 200pl. The cDNA was
stored at -20°C.

2.1.7

Real-time RT (Reverse Transcriptase) - PCR (Polymerase Chain Reaction)

The primers for the reaction were used at 25 pM concentration, containing
12.5pM o f reverse and forward primer respectively. Ten pi 2X SYBR green master mix
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(Fermentas, CA, USA) was used for real-time quantitative PCR with the presence o f lp l
gene-specific primers (Sigma Genosys, Oakville, ON, Canada), 5pi DEPC water and 4pl
cDNA. The reaction was performed on a real-time PCR system (Mini Opticon™
Thermocycler, Bio-Rad). First, the reaction mixture was heated to 95°C for lOmins to
activate the enzymes. Then the mixture was incubated at 95°C for 15secs to denature the
cDNA. The temperature was then lowered to the primer’s annealing temperatures for
20secs. This was followed by incubation at 72°C for 40secs for the DNA polymerase to
synthesize a new DNA strand complementary to the DNA template strand from 5' to 3'
direction. The primer sequences and corresponding annealing temperatures are listed in
(Table 2.1).

2.1.8

Measurement of TNF-a Protein

TNF-a protein concentration in culture medium was measured using a mouse
TNF-a ELISA (enzyme-linked immunosorbent assay) kit (eBiosciences, San Diego, CA,
USA). TNF-a release into lOOpl of culture medium was measured according to the
manufacturer’s instructions. The 96 well ELISA plate was coated with lOOpl/well of
capture antibody (pre-titrated, purified antibody) diluted in IX coating buffer. The
ELISA plate was then incubated overnight at 4°C.

Next day the wells were aspirated and washed 5 times with 250pl/well wash
buffer (IX PBS containing 0.05% Tween-20). The plate was blotted on absorbent paper
to remove any residual buffer. The wells were blocked with 200pl/well IX assay diluents
and incubated at room temperature for 1 hour. The wells were then aspirated and
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Table 2.1 PCR Primer sequences

Primer

Sequence

Size

Annealing
temperature

352 bp

60°C

297 bp

60°C

Í35 bp

60°C

Sense : 5' CCGATGGGTTGTACCTTGTC 3'
TNF-a

Antisense: 5' GGGCT GGGT AG AG A AT GG AT 3'
Sense : 5' AAAGGGCATCCTGGGCTACA 3'

GAPDH

Antisense: 5' CAGTGTTGGGGGCTGAGTTG 3'
Sense : 5' TCTCCTGTGGGATTCCTGAC 3'

SIRT1

Antisense: 5' T GA AGA AT GGT CTT GGGT C TTT 3'
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washed 5 times. Two-fold serial dilution o f the top standards (recombinant cytokine) was
made in IX assay diluent and 100pl/well o f standard solutions were added to the
appropriate wells for generating standard curve and calibrating samples. 1 0 0 pl/well of
the samples was added to the appropriate wells. The plate was then covered and sealed
and incubated overnight at 4°C.

The following day the wells were aspirated and washed 5times. Hundred pl/well
o f detection antibody (pre-titrated, biotin-conjugated antibody) diluted in IX assay
diluent and added to the wells. The plate were sealed and incubated at room temperature
for 1 hour. The wells were again aspirated and washed 5 times. lOOpl/well of avidinHRP enzyme diluted in IX assay diluent was then added to the wells and the plate was
sealed and incubated at room temperature for 30mins. The wells were aspirated and
washed

7times.

This

was

followed

by

addition

of

100pl/well

of

TMB

(tetramethylbenzidine) substrate solution to each well and the plate was incubated at
room temperature for 15mins. Fifty pi o f stop solution (2N H 2SO4) was then added to
each well. The plates were read at 450nm and the data was analyzed. The protein
concentration values were expressed as pg/ml media. The wash buffer and assay diluent
were made sure to be sodium azide free, as it inhibits HRP enzyme activity.

2.1.9

Western blot analysis

To extract the protein from the cardiomyocytes, the cells in the 24 well plate were
washed with IX PBS. One hundred pl/well of cell lysis buffer was added followed by
sonication to extract the cells. The contents o f the well were transferred to 1.5ml tubes
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and 30(xl o f loading buffer was added to each tube. The tubes were vortexed and
incubated at 100°C for 5mins. The samples were then cooled on ice and subjected to
SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis) using 10% or
12% gels followed by electrotransfer to PVDF (Polyvinylidene fluoride, Bio-Rad,
Hercules, CA, USA) membranes. Expression o f specific proteins was determined by
probing the blots using primary antibodies against the relevant corresponding protein
followed by incubation with horseradish peroxidase conjugated secondary antibody
(1/1000, Bio-Rad, Hercules, CA, USA). The protein bands were identified by enhanced
chemiluminescence detection method. The specific protein antibodies used, their
dilutions and the molecular weights o f their respective bands are mentioned in (Table
2 .2 ).

2.1.10

Cardiomyocytes nuclear extraction

To study the transcription factor NF- kB, the nuclei were extracted from cultured
cardiomyocytes using a nuclear extraction kit (Signosis, Inc., Sunnyvale, CA, USA). The
cells in 24 well plates were washed with IX PBS. Two hundred fifty pl/well of IX buffer
containing 1% DTT (Dithiothreitol) solution and 1% Protease inhibitor was added to
each well. The culture plate was kept in an ice box and rocked at 200g for lOmins on a
shaking platform. The cells were released from the dish using a sterile scraper. The
contents o f the well were then transferred to 1.5ml tubes and centrifuged at lOOOOg at
4°C for 5mins. The supernatant was discarded as it is the cytosol extract and the pellets
were kept on ice. Fifty pi of cell lysis buffer was added to each tube followed by
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Table 2.2 Primary antibodies for western blot analysis

Antibody

Dilution

Molecular weight
of protein band

GAPDH
(Cell Signaling Technology,
Pickering, ON)

1:20000

37KD

SIRT1
(Cell Signaling Technology,
Pickering, ON)

1:1000

120KD

Acetylated p53
(Cell Signaling Technology,
Pickering, ON)

1:1000

53KD

Acetylated p65
(Cell Signaling Technology,
Pickering, ON)

1:1000

65KD

Histone H2A
(Cell Signaling Technology,
Pickering, ON)

1:1000

14KD

Total p65
(Applied Biological
Materials (ABM) Inc.,
Richmond, BC, Canada)

1:1000

65KD
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sonication. Sixteen pi of loading buffer was added to each tube. The tubes were vortexed
and incubated at 100°C for 5mins. The samples were then cooled on ice and subjected to
SDS-PAGE.

2.2

In vivo Studies

2.2.1

Animals

Breeding pairs of floxed SIRT1 (S IR T L ) and cardiac-specific over-expressing
ere recombinase (Cre+/+) C57BL/6 mice were purchased from The Jackson Laboratory
and a breeding program was implemented at our animal care facility. The animals were
provided water and food ad libitum and housed in a temperature and humidity controlled
facility with 12-hour light and dark cycles. All animals were used in accordance with the
guidelines of the Canadian Council on Animal Care, and study protocols were approved
by Animal Use Subcommittee at the University of Western Ontario, London, Canada.
Adult (6weeks old) male mice were used for this study.

2.2.2

SIRT1 gene knock-out

Mice bearing the modified SIRT1 gene containing the loxP sites (SIRT1 / ) and
transgenic mice with cardiomyocyte-specific over-expression of ere recombinase (Cre+/+)
under the control o f a-MHC (alpha-myosin heavy chain) were crossed to generate mice
with 1 allele of Sirtl gene deletion (SIRTl+/‘ Cre+/ ). Floxed SIRT1 mice were then bred
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with SIRT1+/' Cre+/' mice to generate homozygous mice with deletion of SIRT1 gene in
both alleles (SIR T l’ ’ Cre+/‘, S IR T l” Cre’ ’), detected by genotyping. The SIRT1
homozygous mice were crossed to generate cardiac specific SIRT1-KO mice.
Genotyping was done and mice carrying the a-MHC-cre transgene were identified. The
knock-out was tamoxifen (Sigma Aldrich, St.Louis, MO, USA, 40 mg/kg/day) induced
by intraperitoneal injections. After 5 days of consecutive tamoxifen injections to Cre+
and Cre’ mice, SIRT1-KO mice were identified by real-time RT-PCR. SIRT1-KO mice
and their wild-type littermates were employed for the study.

2.2.3

Genotyping

Tail samples from mice were placed in 1.5ml tubes and to that lOOpl of PBNDProK (PCR buffer with nonionic detergents - Protenase K, 1% Prok in PBND) solution
was added. The tail samples were cut into small pieces and were placed in 37°C water
incubator and left overnight.

The following day the samples were placed at 50°C for 3 hours. They were then
placed at 100°C for 5 to lOmins and then centrifuged at lOOOOg at 4°C for lOmins.

•

Polymerase chain reaction

To 12.5pl o f PCR mastermix (Fermentas, CA, USA), 0.4pl o f 25pM cre primer
(Sigma Genosys, Oakville, ON, Canada, sense - 5' GCG GTC TGG CAG TAA AAA
CTA TC 3', antisense - 5' GTG AAA CAG CAT TGC TGT CAC TT 3') and 10.1 pi of
DEPC water was added per PCR microtube. To this 2pl of cDNA sample was added and
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the reaction was performed in a PCR system (Thermo Electron Corp. Inc.). First, the
reaction mixture was heated to 94°C for 3mins to activate the enzymes. Then it
underwent 35 cycles o f denaturation at 94°C for 30secs, annealing at 51.7°C for lmin
and extension at 72°C for lmin. For the final elongation, the mixture was incubated at
72°C for 2mins. The reaction was kept at a hold temperature of 10°C.

•

Agarose gel electrophoresis

The PCR products were assessed by a 1% agarose gel containing ethidium
bromide. Five pi o f 6X loading buffer was added to each sample. Fifteen pi from each
tube was added to the wells in the agarose gel and the samples were run at 80V in IX
TAE (Tris-acetate-EDTA) buffer. The Cre+ mice were detected by the presence of 100
bp bands.

2.2.4

Treatment of mice

SIRT1-KO mice and their wild-type littermates were treated with LPS (4mg/kg,
intraperitoneal injections) to induce endotoxemia. After 4hrs of LPS treatment, the mice
hearts were isolated followed by TNF-a mRNA and protein quantification. For RNA
extraction, the TRIzol Reagent was employed. TNF-a mRNA was analysed by real-time
RT-PCR as described earlier. For TNF-a protein concentration measurement, the heart
samples were washed and homogenized in IX PBS and centrifuged at lOOOOg at 4°C for
5min. The protein concentration was determined in the supernatant by Bradford method
using a protein assay kit (Bio-Rad DC™ Protein Assay, Hercules, CA, USA). Two
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hundred pg of tissue protein was used per well for ELISA as explained previously. The
protein concentration values were expressed as ng/mg tissue protein.

2.3

Statistical analysis

Data are reported as mean±SD from at least three independent experiments.
Differences between experiment groups and control groups were compared using one
way analysis o f variance (ANOVA) followed by the Newman-Keuls test. A value of P <
0.05 was considered statistically significant.

Chapter 3: Results
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Section A: The role of SIRT1 in LPS-induced TNF-a synthesis in cardiomyocytes

In vitro results:

3.1

LPS

induces TNF-a expression in cultured C57BL/6 wild-type mice

cardiomyocytes

Cardiomyocytes from wild-type neonatal mice were isolated and cultured in
DMEM supplemented with 1% penicillin/streptomycin and 10% FBS. Twenty four hours
after incubation at 37°C in a humidified atmosphere containing 5% CO 2, the cells grew
in a monolayer of 80% confluent spontaneously beating cells. The cardiomyocytes were
treated with LPS (5pg/ml) and incubated at 37°C for 4 hrs. TNF-a mRNA and protein
release were determined in cardiomyocytes and culture media respectively. It was
detected that the cultured cardiomyocytes of C57BL/6 wild-type mice were highly
responsive to LPS stimulation and TNF-a mRNA (Figure 3.1(a)) and protein (Figure
3.1(b)) production was induced in these cells. Untreated cells were used as control. This
confirmed that the cultured cardiomyocytes were appropriate to perform further
investigations to study the role of SIRT1 in LPS-induced TNF-a synthesis.
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Figure 3.1 TNF-a mRNA and protein expression in LPS-induced cultured
cardiomyocytes

a) Quantification o f TNF-a mRNA relative to GAPDH (house keeping gene) expression
in untreated and LPS (5pg/ml at 37°C for 4hrs) stimulated cells. LPS induced TNF-a
synthesis in cardiomyocytes. Data are mean ± SD, n=3, p<0.05
b) ELISA results showing protein concentration. TNF-a protein release amplified
significantly in cardiomyocytes after LPS (5pg/ml at 37°C for 4hrs) stimulation
compared to untreated cells. Data are mean ± SD, n=3, p<0.05
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3.2

Confirmation of SIRT1 gene knockdown

To detect the role of SIRT1

in LPS stimulated TNF-a synthesis in

cardiomyocytes, the SIRT1 gene was knocked down by siRNA transfection. A
scrambled siRNA was used as control. Twenty-four hours after transfection with siRNA,
the knockdown was confirmed in cardiomyocytes by western blot analysis. Results
showed that transfection of SIRT1 siRNA downregulated SIRT1 protein (Figure 3.2).
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Control siRNA

SIRT1 siRNA

GAPDH
SIRT1

Figure 3.2 Knockdown of SIRT1 gene

The above is a representative blot for GAPDH (house keeping protein) and SIRT1
protein from 3 different cell cultures. There is less SIRT1 protein after transfection with
SIRT1 siRNA. This confirmed that SIRT1 gene was knocked down in cardiomyocytes.
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3.3

Effect of SIRT1 knockdown or SIRT1 inhibition on LPS-induced TNF-a

expression in vitro

Twenty-four hours after transfection with SIRT1 siRNA or a scrambled siRNA,
the cardiomyocytes were treated with LPS (5pg/ml) and incubated at 37°C for 4hrs. The
cells were then harvested and real-time RT-PCR was done to detect whether knock-down
o f SIRT1 gene by siRNA decreased TNF-a synthesis compared to the control. It was
observed that SIRT1 deficiency resulted in a significant depletion o f TNF-a transcription
in LPS stimulated cardiomyocytes (Figure 3.3(a)). This data demonstrated that SIRT1
plays an important role in LPS-induced TNF-a expression in cardiomyocytes.

Nicotinamide is a known pharmacological inhibitor of SIRT1 activity [80], To
further demonstrate that SIRT1 plays a role in LPS-induced TNF-a expression, the cells
were treated with nicotinamide (50pM) or vehicle in combination with LPS (5pg/ml) and
incubated at 37°C. Four hours post-treatment, the cells were harvested and GAPDH and
TNF-a expression was quantified to determine if hindering SIRT1 activity attenuates
TNF-a synthesis. Results showed that inhibition of S1RT1 activity by nicotinamide in
LPS stimulated cells considerably reduced TNF-a mRNA level compared to the vehicle
treated cells (Figure 3.3(b)).
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Figure 3.3 LPS-induced TN F-a expression in vitro after SIRT1 gene knock-down or
inhibition of SIRT1 activity

a) The TNF-a synthesis post LPS (5pg/ml at 37°C for 4hrs) treatment is lower in cells in
which the SIRT1 gene was knocked down (SIRT1 siRNA) compared to the negative
control (scrambled siRNA). Data are mean ± SD, n=3, p<0.05
b) Quantification of TNF-a mRNA expression in LPS (5pg/ml at 37°C for 4hrs)
stimulated cells when untreated or treated with nicotinamide (50pM at 37°C for 4hrs).
Inhibition of SIRT1 activity by nicotinamide reduced TNF-a transcription in LPS
stimulated cardiomyocytes. Data are mean ± SD, n=3, p<0.05
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3.4

LPS-induced TN F-a expression in vitro post stimulation of SIRT1 activity

Subsequent to confirming that inhibition of SIRT1 activity down-regulates TNFa synthesis in LPS treated cells, we sought to validate that stimulating SIRT1 activity
will enhance TNF-a expression. Resveratrol has been reported to be a pharmacological
activator of SIRT1 activity [100], The cultured cardiomyocytes were treated with
resveratrol (lOpM) or vehicle in combination with LPS (5pg/ml) and incubated at 37°C.
Four hours post-treatment, the cells were harvested and GAPDH and TNF-a expression
was quantified to determine whether activation of SIRT1 activity promoted TNF-a
transcription. Stimulation of SIRT1 activity by resveratrol significantly enhanced LPS
mediated TNF-a expression in cardiomyocytes compared to the vehicle treated cells
(Figure 3.4).

\
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LPS

LPS+Resveratrol

Figure 3.4 Assessment of SIRT1 activation on LPS-induced TNF-a expression in
vitro

Real-time RT-PCR results of TNF-a mRNA expression relative to GAPDH
expression in LPS (5pg/ml at 37°C for 4hrs) stimulated cells when untreated or treated
with resveratrol (10pM at 37°C for 4hrs). Inducing SIRT1 activity by resveratrol
increased TNF-a expression in LPS stimulated cardiomyocytes. Data are mean ± SD,
n=4, p<0.05
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3.5

NAM PT/NAD+ are upstream of SIRT1 in LPS-induced TNF-a expression in

cardiomyocytes

SIRT1 is a NAD+ (nicotinamide adenine dinucleotide) dependent enzyme [62],
Inhibition or addition of NAD+will decrease or increase the SIRT1 activity respectively
and therefore will further help validate the involvement of SIRT1 in LPS-induced TNF-a
expression.

The cultured cardiomyocytes were treated with NAD+ (5pM) or vehicle in
combination with LPS (5pg/ml) and incubated at 37°C for 4hrs. Post-treatment, the cells
were harvested and GAPDH and TNF-a expression was quantified to determine whether
increasing the NAD+ in the cells enhanced TNF-a expression. It was observed that
increasing the enzymatic activity of SIRT1 with addition of NAD+ to the culture media
increased the TNF-a synthesis in the cardiomyocytes compared to the vehicle treated
cells (Figure 3.5(a)).

Subsequent to confirming that stimulating SIRT1 activity by NAD+ up-regulates
TNF-a synthesis in LPS treated cells, we sought to validate that inhibiting NAD+ will
reduce TNF-a expression. NAMPT (nicotinamide phosphoribosyltransferase) is a crucial
enzyme in the NAD+ salvage pathway and plays a role in NAD+ synthesis [103]. FK866
(N-[4-(l-benzoyl-4-piperidinyl)butyl]-3-(3-pyridinyl)-2E-propenamide) has been shown
to be a highly specific non-competitive inhibitor of NAMPT [105]. The cardiomyocytes
were treated with FK.866 (InM) or vehicle in combination with LPS (5pg/ml) and
incubated at 37°C. Four hours post-treatment, real-time RT-PCR was performed to
quantify GAPDH and TNF-a expression to assess whether hindering NAD+ production

45

in the cells decreased the amount of TNF-a mRNA. Results revealed that inhibition of
NAMPT significantly attenuated TNF-a expression in cardiomyocytes (Figure 3.5(b)).
This data demonstrated that NAMPT/NAD+ are upstream in the pathway and further
verified that SIRT1 signalling is significant in amplifying LPS mediated TNF-a
transcription.
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LPS

LPS+NAD+

LPS

LPS+FK866

Figure 3.5 Effect of NAD+ stim ulation o r NAMPT inhibition on LPS-induced TNFa expression in vitro

a) TNF-a mRNA expression relative to GAPDH expression in LPS (5pg/ml at 37°C for
4hrs) stimulated cells when untreated or treated with NAD+ (5pM at 37°C for 4hrs).
NAD+ stimulated TNF-a synthesis in LPS treated cardiomyocytes. Data are mean ±
SD, n=3, p<0.05
b) TNF-a mRNA expression relative to GAPDH expression in LPS (5pg/ml at 37°C for
4hrs) stimulated cells when untreated or treated with FK866 (InM at 37°C for 4hrs).
FK866, by hindering NAMPT activity, reduced cellular NAD+ level and hence
reduced TNF-a transcription in LPS stimulated cardiomyocytes. Data are mean ±
SD, n=4, p<0.05
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3.6

TN F-a protein

release after SIRT1 inhibition or activation in LPS

stim ulated cardiomyocytes.

To verify that TNF-a protein expression correlated with real-time RT-PCR
results when the cells were treated with the same pharmacological agents, ELISA
(enzyme-linked immunosorbent assay) was performed. The cells were once again treated
with nicotinamide (50pM) or resveratrol (lOpM) in combination with LPS (5pg/ml) to
confirm whether the amount of TNF-a protein release decreases or increases respectively
in the culture medium. The cells were incubated at 37°C for 4hrs. Untreated cells and
cells treated with nicotinamide or resveratrol alone were used as control. Post-treatment,
lOOpl of the culture media was taken to perform the protein quantification assay. TNF-a
protein increased in culture media after LPS stimulation of cardiomyocytes compared to
the control cells. When the cells were treated with LPS plus nicotinamide, there was a
reduction in TNF-a protein concentration. Whereas, when the cells were treated with
LPS plus resveratrol, there was an increase in TNF-a protein concentration in the culture
medium (Figure 3.6). This data hence further substantiated the important role of SIRT1
in stimulating LPS-induced TNF-a expression in cardiomyocytes.
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Figure 3.6 TN F-a protein release in culture media

ELISA results showing protein concentration. Cells not treated with LPS show
reduction in TNF-a protein when SIRT1 activity is inhibited by nicotinamide (50pM at
37°C for 4hrs) and up-regulation in TNF-a protein when SIRT1 is activated by
resveratrol (lOpM at 37°C for 4hrs). TNF-a protein amplified significantly in
cardiomyocytes after LPS (5pg/ml at 37°C for 4hrs) stimulation. When the LPS
stimulated cells were treated with nicotinamide, there was down-regulation of TNF-a
protein. In contrast, when LPS stimulated cells were treated with resveratrol, there was
an increase in TNF-a protein in the culture medium. Data are mean ± SD, n=3, p<0.05
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In vivo results:

3.7

Genotyping

Subsequent to confirming that S1RT1 plays an important role downstream in the
signalling pathway in LPS mediated TNF-a expression in vitro, we sought to validate
this in vivo. To study the importance o f SIRT1 in the LPS signalling and the TNF-a
production, tamoxifen-inducible and cardiac-specific SIRT1 knockout mice were used.

To determine the presence of ere transgene, tail samples from mice were taken
and PCR was performed. The PCR products were detected by 1% agarose gel
electrophoresis, in which the ere expression (lOObp) was observed. The mice showing
positive bands were identified as Cre+ mice (Figure 3.7). Cre+ and Cre' mice were given
consecutive IP injections of tamoxifen (40 mg/kg/day) for 5 days to induce cardiac
specific deletion o f SIRT1 in floxed SIRT1 mice with cre transgene.

\
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Figure 3.7 Genotyping for mice carrying the ere gene

Representative gel showing presence or absence of a-MHC-cre transgene. Lanes 1,
2, 4, 5 and 8 indicate Cre+mice. Lanes 3, 6, 7 indicate mice lacking the ere gene.
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3.8

C onfirm ation of SIRT1 gene knock-out mice

Tamoxifen (40 mg/kg/day for 5 days) induced cardiac specific SIRT1 deletion
was confirmed by real-time RT-PCR. The GAPDH and SIRT1 expression was quantified
in the heart tissue of the mice. Tissue from wild-type mice was employed as control.
Results showed a significant reduction in SIRT1 mRNA from SIRT1 gene knock-out
mice after tamoxifen injections (Figure 3.8).

\
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Figure 3.8 Determining SIRT1-KO mice

SIRT1 mRNA expression relative to GAPDH expression in wild-type and
tamoxifen (40 mg/kg/day for 5 days) treated Cre+ mice. Reduction in SIRT1 expression
confirmed knock-out of SIRT1 gene in the Cre+ mice. Data are mean ± SD, n=3, p<0.05
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3.9

C om paring LPS-induced TN F-a mRNA and protein expression in SIRT1-

KO and wild-type mice

One month after tamoxifen injections, the SIRT1-KO mice and their wild-type
littermates were injected with LPS (4mg/kg) intraperitoneally to induce endotoxemia.
Four hours post LPS treatment, the mice hearts were isolated and real-time RT-PCR was
done to quantify GAPDH and TNF-a mRNA to determine whether SIRT1-KO mice had
lower TNF-a synthesis compared to wild-type mice after LPS treatment. Control animals
consisted o f SIRT1-KO mice and wild-type mice given no treatment. Results indicated a
substantial decrease in TNF-a mRNA in SIRT1-KO mice compared to the wild-type
mice after LPS treatment (Figure 3.9(a)).

Similarly, the heart tissue from the treated and control mice were homogenized in
IX PBS and ELISA was performed to quantify TNF-a protein concentration. The results
revealed that the TNF-a protein was considerably lower in SIRT1-KO mice compared to
the wild-type mice after LPS treatment (Figure 3.9(b)). The in vivo data correlated with
the in vitro data, further corroborating the downstream role of S1RT1 in LPS mediated
TNF-a expression in cardiomyocytes.
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Figure 3.9 Assessing LPS-induced TN F-a mRNA and protein expression in SIRT1KO and wild-type mice

a)

TNF-a mRNA expression relative to GAPDH expression in untreated or LPS
(4mg/kg for 4hrs) treated wild-type (WT) and SIRT-KO mice. No difference is seen
in the TNF-a expression in WT and SIRT1-KO mice, when not treated with LPS.
SIRT1-KO mice show considerable reduction in TNF-a synthesis compared to WT
mice post LPS treatment. Data are mean ± SD, n=6, p<0.05

b)

ELISA results showing protein concentration in ng/mg. Untreated WT and SIRT1KO mice show no difference in TNF-a protein concentration. In LPS (4mg/kg for
4hrs) treated mice, a significant decrease is seen in TNF-a protein in SIRT1-KO
mice compared to the WT mice. Data are mean ± SD, n=6, p<0.05
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Section B: To determ ine LPS increased SIRT1 activity in cardiomyocytes

3.10

To ascertain th at doxorubicin induces p53 acetylation in cultured C57BL/6

wild-type mice cardiomyocytes

Doxorubicin is a drug used in chemotherapy and is known to induce p53
acetylation [106], P53 is a tumor suppressor protein involved in regulating cell cycle
[107],

To induce p53 acetylation, the cultured cardiomyocytes were treated with
doxorubicin (1 pM) and incubated at 37°C for 2hrs. The cells were then harvested by cell
lysis buffer and western blot analysis was done to assess p53 acetylation. Untreated cells
were used as control. Results demonstrated that doxorubicin induces p53 acetylation in
neonatal mice cardiomyocytes (Figure 3.10).
\
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Figure 3.10 Expression of acetylated p53 in cultured cardiomyocytes on
doxorubicin treatm ent

The above is a representative blot for GAPDH and acetylated p53 protein from 3
different cell cultures. Acetylation of p53 is strongly induced by doxorubicin (lpM at
37°C for 2hrs) in cultured cardiomyocytes. Untreated cells show no acetylated p53.
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3.11

To confirm th at LPS causes deacetylation of p53 by increasing SIRT1

activity

SIRT1 is an important enzyme for p53 deacetylation [106], If LPS increases
SIRT1 activity, doxorubicin-induced acetylated p53 will be decreased in LPS stimulated
cardiomyocytes. To prove this, cardiomyocytes were incubated with doxorubicin (lpM )
for 2 hours and then with LPS (5pg/ml) for another 2 hours at 37°C. Post-treatment the
cultured cells were harvested by cell lysis buffer and western blot was performed to
assess p53 acetylation. Results showed that LPS decreased the doxorubicin induced p53
acetylation in neonatal mice cardiomyocytes when compared to cells treated with
doxorubicin alone (Figure 3.11(a)). This result suggested that LPS may increase SIRT1
activity in cardiomyocytes.

Conventional histone deacetylases (FIDAC) also play a role in p53 deacetylation
[108], TSA (Trichostatin A) is a known HDAC inhibitor [109], To confirm that the
deacetylation was due to an increase in SIRT1 activity but not conventional HDAC, the
cells were treated with doxorubicin (lpM ), LPS (5pg/ml) and TSA (lpM ). The cells
were first treated with doxorubicin for 2hrs, followed by 2hrs of LPS and TSA treatment
at 37°C. Post-treatment, the cells were harvested and western blot was performed to
analyze the p53 acetylation. Results indicated that cells treated with doxorubicin and
TSA had higher acetylated p53 compared to cells treated with doxorubicin alone, due to
the inhibition of HDAC activity by TSA. However, a decrease in acetylated p53 was
observed when the cells were treated with doxorubicin, TSA and LPS (Figure 3.11(b)).

58

Cellular p53 is a substrate of SIRT1 and not SIRT 2 to 7 [73, 110]. Deacetylation
of p53 by HD AC and SIRT1 stops p53 function when transcriptional activation of target
gene is not needed [73, 110]. Both HDAC and S1RT1 are critical for p53-dependent
stress response [73, 110]. As cellular p53 is a substrate for only SIRT1 and not S1RT2-7,
this data also suggest that the deacetylation was due to SIRT1.

\
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Figure 3.11 Deacetylation of p53 by increasing SIRT1 activity

a) Is a representative blot for GAPDH and acetylated p53 protein from 3 different cell
cultures. The lower panel blot confirms that doxorubicin (lpM at 37°C for 2hrs)
induced acetylated p53 is reduced by LPS (5pg/ml at 37°C for 2hrs) treatment of
cultured cardiomyocytes. Cells untreated with doxorubicin show no acetylated p53.
b) Is a representative blot for GAPDH and acetylated p53 protein from 3 different cell
cultures. The lower panel blot confirms that TSA (lpM at 37°C for 2hrs) by inhibiting
HDAC, increases acetylated p53 in doxorubicin (lpM at 37°C for 2hrs) treated cells.
This can be inhibited by addition of LPS (5pg/ml at 37°C for 2hrs), as it increases
SIRT1 activity.
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Section C: To determ ine w hether SIRT1 prom otes TN F-a expression in LPS
stim ulated cardiomyocytes through NF-kB activation.

3.12

To determine that SIRT1 regulates NF-kB activation by its deacetylase

activity

NF- kB (nuclear factor-kappa B) is a major transcription factor of TNF-a [20].
Western blot analysis was done to establish whether NF-kB is downstream of SIRT1 in
the LPS signalling. P65 is a subunit of the NF-kB heterodimer [20], Cultured cells were
treated with LPS (5pg/ml) and nicotinamide (50pM) to determine whether the amount of
acetylated p65 increases due to inhibition o f SIRT1 activity. Resveratrol (lOpM) was
also used to treat LPS-induced cardiomyocytes to confirm whether SIRT1 activation
decreases the amount of acetylated p65. The cells were incubated at 37°C for 4hrs. Post
treatment, the cells were harvested by cell lysis buffer and western blot was performed to
assess p65 acetylation. Results showed that acetylated p65 increased in cells treated with
LPS. Cells treated with LPS plus nicotinamide showed a further increase in acetylated
p65. In contrast, activation of SIRT1 by resveratrol slightly decreased acetylated p65 in
LPS treated cells, even though not statistically significant (Figure 3.12). This suggested
that SIRT1 signalling is associated with p65 deacetylation.

61

LPS+

LPS+

GAPDH
Acetylated p65

^ 3 7 KD
^65KD

Figure 3.12 S1RT1 regulates NF- kB activation by its deacetylase activity

Above is a representative blot for GAPDH and acetylated p65 protein from 3
different cell cultures. The lower panel blot demonstrates that LPS (5pg/ml at 37°C for
4hrs) increases acetylated p65. LPS-induced acetylation of p65 can be slightly inhibited
by resveratrol (lOpM at 37°C for 4hrs) or augmented considerably by nicotinamide
(50pM at 37°C for 4hrs).
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3.13

To determ ine NF- k B activation can be prevented by inhibiting SIRT1

activity

NF- kB transcription factor translocates from the cytosol into the nucleus upon
activation by LPS and causes cytokine expression [20], Nuclear extraction of
cardiomyocytes was done to determine if the total p65 increases in the nuclei of the cells
treated with LPS and whether this can be inhibited by inhibiting SIRT1 activity. To
detect this, cultured cells were treated with LPS (5pg/ml) and nicotinamide (50pM). The
cells were incubated at 37°C for 4hrs. Post-treatment the cells were harvested and
western blot analysis was done to detect total p65 translocation. Histone H2A protein
expression was used as control, as it is present only in the nuclei. Results showed that
LPS increased the total p65 in the nuclei of the cardiomyocytes compared to the
untreated cells. When the cells were treated with nicotinamide in addition to LPS, a
decrease in total p65 was seen due to inhibition o f SIRT1 activity (Figure 3.13). This
data

suggested

that

SIRT1

promotes

TNF-a

cardiomyocytes through the activation of NF- kB.

expression

in LPS
V

stimulated
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Figure 3.13 Inhibition of NF- k B activation by hindering SIRT1 activity

Above is a representative blot for Histone H2A and total p65 protein from 3
different cell cultures. The lower panel blot demonstrates that total p65 increases in the
nuclei on LPS (5pg/ml at 37°C for 4hrs) treatment of cardiomyocytes. This can be
inhibited by addition of nicotinamide (50pM at 37°C for 4hrs) to the LPS stimulated
cells.

C hapter 4: Discussion
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Myocardial dysfunction is a common clinical manifestation in sepsis and septic
shock and many difficulties are encountered in terms of clinical treatment. Efforts
continue to understand the molecular basis of this process and to protect the heart from
this complication. While the exact cause o f myocardial dysfunction during sepsis and
septic shock is not completely understood, excessive production of proinflammatory
cytokines, particularly TNF-a has been shown to play a significant role in cardiac failure
[38, 39], Macrophages and monocytes are considered to be a predominant source of
circulating TNF-a in response to LPS stimulation, but cardiomyocytes themselves act as
a major local source o f TNF-a in the myocardium [37]. Activation of TNF-a expression
is controlled by multiple mechanisms and in recent years, researchers have been engaged
toward the identification of signal transduction pathways that positively regulate TNF-a
expression in LPS stimulated cardiomyocytes. Flowever, the exact mechanism by which
LPS induces TNF-a in the myocardium during sepsis remains not fully understood.

This study demonstrates that SIRT1 plays an important role in TNF-a expression
\
through NF-kB activation in cardiomyocytes. Several lines of evidence support this
conclusion. Both gene silencing o f SIRT1 by siRNA transfection and inhibition of
SIRT1 activity by nicotinamide induced a significant depletion of TNF-a transcription in
LPS stimulated cultured cardiomyocytes. In contrast, resveratrol, a known SIRT1
activator enhanced LPS mediated TNF-a synthesis. TNF-a protein expression also
corresponded with real-time RT-PCR results when the cells were treated with the same
pharmacological agents. TNF-a protein level of LPS stimulated cardiomyocytes was
detected to decrease and increase upon nicotinamide and resveratrol treatment
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respectively. This data strongly suggested the involvement of SIRT1 in LPS-induced
TNF-a expression in cardiomyocytes.

Furthermore, to confirm that SIRT1 is essential in vivo for cardiomyocytes to
express TNF-a in response to LPS, the SIRT1 gene was knocked out in adult C57BL/6
mice. It was noticed that TNF-a mRNA and protein was considerably lower in SIRT1
deficient mice compared to the wild-type mice after LPS treatment. The in vivo data
correlated with the in vitro data, further validating the downstream role of SIRT1 in LPS
mediated TNF-a expression in cardiomyocytes.

Nicotinamide has been shown to inhibit the production of key inflammatory
mediators such as NO (nitric oxide) and cytokines [111-113], However, the mechanisms
by which nicotinamide affects an inflammatory response has not been clearly established
due to its wide range o f putative targets [114], Inhibition of sirtuins has now emerged as
a potential mechanism by which nicotinamide inhibits an inflammatory response [102].
These observations are shifting interest in nicotinamide from being a simple nutrient to a
pharmacological agent able to interfere with the activity of sirtuins and various other
enzymes, such as PARP-1 (poly ADP-ribose polymerases-1) and 3',5'- cyclic AMP
phosphodiesterase [115, 116].

The enzyme NAMPT is known to be upstream and an important regulator of
sirtuin activity by maintaining the availability of its substrate NAD+ [117]. The capacity
o f immune cells to produce TNF-a has been directly correlated with intracellular NAD+
level [102], NAD+ was essentially known as a coenzyme involved in redox reactions in
metabolic pathways. In the last few decades, a number of studies have uncovered an
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additional function o f NAD+ in cellular physiology by being a substrate for a growing
group o f NAD+ dependent enzymes, such as sirtuins [118]. It is therefore presently
believed that intracellular NAD+ and nicotinamide levels may regulate numerous cellular
reactions by modulating the activity of sirtuins [119].

By altering availability of upstream molecules in vitro we indirectly influenced
the SIRT1 activity to further verify its involvement in LPS-induced TNF-a synthesis.
Inhibition of NAMPT by FK866 reduced TNF-a synthesis, whereas NAD+ promoted the
TNF-a expression in LPS treated cardiomyocytes, verifying that SIRT1 signalling is
significant in amplifying LPS mediated TNF-a transcription. This data also delineates a
relationship between metabolism and the inflammatory response in the myocardium, by
uncovering a role o f NAD+ dependent SIRT1 in TNF-a production. The intracellular
concentration o f NAD+ and nicotinamide will hence play contrasting roles in regulation
and synthesis of TNF-a in the cardiomyocytes. NAMPT expression may also represent a
regulatory mechanism, providing adequate intracellular NAD+ levels required for the
effective function of SIRT1 and other possibly involved NAD+ consuming enzymes.
Acute administration of FK866 in vivo has previously been shown to significantly inhibit
TNF-a secretion by immune cells in response to LPS with limited toxicity [120],

Deacetylase activity o f SIRT1 has been shown to modulate p53 functions and
regulate apoptosis and tumor progression in cardiomyocytes

[106,

121,

122],

Doxorubicin is a drug with a wide spectrum of clinical antineoplastic activity and is
known to induce p53 acetylation [106], In our study, it was further observed in vitro that
doxorubicin induced acetylated p53 decreases upon LPS stimulation of the cells, even if
HDAC (histone deacetylase) was inhibited. This confirmed that LPS enhanced
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deacetylation was due to increase in SIRT1 activity in cardiomyocytes. It was
additionally demonstrated that NF- kB was the transcription factor downstream of SIRT1
in LPS-induced TNF-a expression.

PARP-1 (poly ADP-ribose polymerases-1) has been shown to act as a
transcriptional activator of NF- kB [123]. Nuclear enzyme family known as PARPs have
been recently identified in mammals as NAD+ dependent enzymes that catalyze protein
modifications [124]. PARP-1 molecules were thus considered to be molecular link
between NAD+ metabolism and inflammation [125], However, sirtuins are emerging as
another significant NAD+ dependent enzyme involved in controlling NF-kB activity and
regulating the inflammatory response [126], In our studies it was detected that the
amount of acetylated p65 increased and decreased upon nicotinamide and resveratrol
treatment respectively in the cardiomyocytes. This data suggested that SIRT1 regulates
NF- kB by its deacetylase activity. NF-kB activation and translocation from the cytosol to
the nucleus upon LPS treatment could also be prevented by inhibiting SIRT1 activity,
further substantiating that NF-kB was the transcription factor involved downstream of
SIRT1. SIRT1 inhibition of NF-kB activity to reduce TNF-a production in epithelial
lung cell line and macrophages has been documented in previous reports [104, 127], Our
results, on the contrary suggest that in LPS stimulated cardiomyocytes, SIRT1 plays an
important role in inducing TNF-a expression through NF- kB activation. It is currently
unknown what causes this discrepancy. However, these data suggest that SIRT1 may
play a distinct role in different cell types in terms of regulating TNF-a expression.

In recent years, much attention has been paid to find molecular targets to reduce
TNF-a production in septic hearts and help minimize myocardial depression. Members
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of the sirtuin family, specifically SIRT1, have become a focus of intense cardiovascular
research. SIRT1 initiates several signalling events relevant to cardioprotection, including
activation o f eNOS (endothelial nitric oxide synthase) and insulin receptor signalling
[86, 128], In cardiac cellular models, SIRT1 has been found to be protective against
hypertrophic, oxidative and metabolic stress resulting in increased cell survival [96, 129,
130]. However, the role of SIRT1 in TNF-a production has not been demonstrated in the
myocardium during sepsis. This is the first time it has been detected that SIRT1 is upregulated in the cardiomyocytes during sepsis and this enhances TNF-a synthesis. Future
study is required to examine the functional significance of SIRT1 signalling during
endotoxemia and whether septic myocardial dysfunction can be ameliorated by
inhibiting SIRT1 activity.

Since, none of the present available strategies show adequate effectiveness to
reduce TNF-a production and myocardial dysfunction, the potential o f targeting SIRT1
signalling pathways may open up new therapeutic avenues. To manage a balance
between TNF-a positive and negative signalling pathways will also be very essential in
tackling this condition. Further research is warranted to eventually dissect the function of
S1RT1 and possibly other sirtuins in LPS-mediated TNF-a expression. Upstream and
downstream mechanisms need further investigations to identify other possible molecules
involved in this signalling pathway. Though, as the cause of myocardial dysfunction in
sepsis is multi-factorial, it will be important to identify all the individual contributing
factors and the underlying mechanisms to generate worthwhile therapeutic targets. Thus,
alternate pathways will remain a challenge to inhibit TNF-a synthesis and to attenuate
myocardial dysfunction in endotoxemic hearts. Amelioration of other cytokines, such as
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IL-6 (interleukin-6) and IL-ip (interleukin-1(3) and complement molecules, such as C5a
(complement component 5a) involved in depressing myocardial contractility will also be
critical in suppressing myocardial dysfunction.

In summary, the present study has demonstrated a novel signalling mechanism by
which SIRT1 promotes TNF-a expression in LPS stimulated cardiomyocytes through
NF- kB activation and NAMPT/NAD+ are upstream in the signalling pathway. These
findings may therefore have prospective therapeutic implications in finding effective
treatment for myocardial depression during sepsis.

\
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